Organoid Kit Market Report 2025

The organoid kit market size has grown rapidly in recent years. It will grow from $1.13 billion in 2024 to $1.31 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth during the historic period was driven by increasing research in stem cell biology, expanding applications in drug toxicity testing, growing use of organoids in cancer research, wider availability of specialized cell culture media, and rising importance of animal-free testing models.

The organoid kit market size is expected to see rapid growth in the next few years. It will grow to $2.37 billion in 2029 at a compound annual growth rate (CAGR) of 16%. The growth during the forecast period is fueled by greater integration with artificial intelligence and automation, increased use of organoids for gene editing applications, growth in the development of customized organoid kits, rising funding for next-generation 3D bioprinting technologies, and expanding adoption of organoids for rare disease modeling. The primary trends in the forecast period include advancements in organ-on-a-chip technology, integration of AI for personalized medicine, innovation in 3D cell culture systems, expansion of organoid-based drug discovery platforms, and collaborations between biotech firms and academic institutions.

The rising incidence of infectious diseases is expected to drive the growth of the organoid kit market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, which can spread from person to person either directly or indirectly. The increase in infectious diseases can be attributed to factors such as poor sanitation and overcrowding, which facilitate pathogen transmission and elevate infection rates. Organoid kits help combat infectious diseases by enabling researchers to model human tissues in the lab, allowing precise examination of pathogen behavior, infection mechanisms, and the testing of potential treatments. For example, in 2025, the UK Health Security Agency (UKHSA), a UK-based government agency, reported that tuberculosis (TB) continues to pose a significant public health challenge in England. Recent data shows an 11% rise in tuberculosis cases, with nearly 500 more cases reported in 2023 compared to 2022. As the incidence of infectious diseases continues to grow, the demand for organoid kits is expected to increase.

Companies in the organoid kit market are developing innovative solutions to improve consistency and scalability in organoid studies. One such innovation is rapid aggregate formation, which enables researchers to quickly generate thousands of uniform pluripotent stem cell aggregates in a single day, significantly reducing organoid development time. For instance, in June 2025, Pluristyx Inc., a US-based biotechnology company, introduced its PluriForm Organoid Kit, designed to streamline the creation of pluripotent stem cell aggregates and speed up organoid development. The kit offers a ready-to-use platform that shortens the timeline for generating mature organoids from months to just weeks. It integrates optimized growth media and standardized protocols, ensuring reproducibility across various cell types and supporting high-throughput applications for large-scale disease modeling and drug screening.

In April 2024, Sartorius AG, a Germany-based biotechnology company, formed a partnership with TheWell Bioscience Inc. to advance 3D cell culture and organoid research. This collaboration aims to enhance Sartorius AG’s 3D cell culture solutions by integrating TheWell Bioscience’s specialized hydrogel platforms, which are designed for use in organoid and spheroid research. TheWell Bioscience Inc., a US-based biotechnology company, specializes in 3D cell culture and organoid technology, leveraging advanced hydrogel platforms to support cellular modeling.

Major players in the organoid kit market are Thermo Fisher Scientific Inc., bioGenous Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Molecular Devices LLC, Takara Bio Inc., American Type Culture Collection (ATCC), ACROBiosystems Inc., Crown Bioscience International, Creative Biolabs Inc., Emulate Inc., CN Bio Innovations Limited, Novoprotein Scientific Inc., MedChemExpress LLC, Xylyx Bio Inc., MIMETAS B.V., Prellis Biologics Inc., TheWell Bioscience Inc., InSCREENeX GmbH, AMS Biotechnology (Europe) Limited (AMSBIO).

North America was the largest region in the organoid kit market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in organoid kit report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the organoid kit market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Organoid kits are specialized laboratory toolsets designed to culture and grow miniaturized, three-dimensional organ-like structures from stem cells. These kits provide essential reagents, growth factors, and protocols to replicate organ development and function in vitro. They are widely applied in biomedical research, drug discovery, and disease modeling.

The primary types of organoid kits are brain organoids, kidney organoids, intestinal organoids, liver organoids, and others. Brain organoids are three-dimensional, miniaturized models of the human brain developed for research and therapeutic applications. Technologies used include 3D cell culture, microfluidics, bioprinting, and electrospinning. Source types include human-derived, animal-derived, and cell line-derived organoids. Applications span drug discovery and development, disease modeling, personalized medicine, regenerative medicine, and others. Key end users include research institutes, pharmaceutical companies, contract research organizations, and biotech companies.

The organoid kit market research report is one of a series of new reports that provides organoid kit market statistics, including the organoid kit industry global market size, regional shares, competitors with the organoid kit market share, detailed organoid kit market segments, market trends, and opportunities, and any further data you may need to thrive in the organoid kit industry. This organoid kit market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The organoid kit market consists of revenues earned by entities by providing services such as organoid co-culture kits, organoid-on-a-chip integration services, and organoid toxicology testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The organoid kit market also includes sales of organoid biobanking kits, organoid functional assay kits, and organoid gene editing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.